May 28, 2026 - 07:07

Marvell Technology reported record revenue for its first fiscal quarter of 2027, surpassing analyst expectations and signaling a strong start to the year. The company also raised its revenue outlook for both fiscal 2027 and fiscal 2028, pointing to accelerating demand across its data center portfolio and ongoing customer investment in artificial intelligence infrastructure.
During the earnings call, executives highlighted that growth was driven by custom AI silicon, networking chips, and electro-optics used in high-performance computing clusters. The company's data center segment posted a significant year-over-year increase, now accounting for the majority of total revenue. Management noted that enterprise and carrier markets remained soft, but the strength in AI-related spending more than offset those headwinds.
Marvell's guidance for the current quarter came in above consensus, with leadership expressing confidence that the company is well-positioned to capture a larger share of the AI hardware market. The raised long-term outlook reflects expectations that demand for custom ASICs and interconnect technology will remain robust through at least the next two fiscal years. Shares moved higher in after-hours trading as investors reacted to the stronger-than-expected results and the upbeat forecast.
September 30, 2026 - 01:50
Space Force Turns to Laser Systems to Shield Launch Sites from Drone ThreatsThe U.S. Space Force is moving forward with plans to deploy laser technology as part of a broader effort to defend its launch facilities from unauthorized drones. The initiative focuses on...
September 29, 2026 - 04:58
DIU Seeks Investors in Counter-Unmanned Systems TechnologyThe Defense Innovation Unit is looking for private investors to back companies working on counter unmanned systems technology. The effort targets firms building tools to detect, track, and disable...
September 28, 2026 - 02:02
Novo Nordisk (CPSE:NOVO B) Secures Long-Acting Injectable Technology In €1.165 Billion Nanexa Licensing AgreementNovo Nordisk has entered a global licensing agreement with Swedish drug delivery company Nanexa, valued at up to 1.165 billion euros. The deal centers on Nanexa`s PharmaShell technology, a platform...
September 27, 2026 - 08:32
New Biochip Enables Real-Time Tracking of Parkinson's Treatment ResponseResearchers have created a biochip technology that allows for real-time monitoring of how Parkinson`s disease patients respond to treatment. The development comes from a team working on advanced...